{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T03:09:26Z","timestamp":1788318566130,"version":"build-2803163510"},"reference-count":7,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2024,1,1]]},"abstract":"<jats:sec id=\"ab-des230001-1\"><jats:title>Clinical Question<\/jats:title><jats:p>What are the most effective systemic medications to treat plaque psoriasis?<\/jats:p><\/jats:sec><jats:sec id=\"ab-des230001-2\"><jats:title>Bottom Line<\/jats:title><jats:p>The most effective drugs for psoriasis were infliximab, bimekizumab, ixekizumab, and risankizumab, and the clinical effectiveness was similar when these 4 drugs were compared against one another. No statistically significant differences in serious adverse events were identified in any of the drugs compared with placebo. The main limitations of this meta-analysis include the lack of assessment of clinical effectiveness beyond 52 weeks and the lack of safety assessments for nonserious adverse events.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamadermatol.2023.4445","type":"journal-article","created":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T16:01:22Z","timestamp":1700064082000},"page":"99","source":"Crossref","is-referenced-by-count":10,"title":["The Best Psoriasis Medications Emerge"],"prefix":"10.1001","volume":"160","author":[{"given":"Andrew","family":"Blauvelt","sequence":"first","affiliation":[{"name":"Oregon Medical Research Center, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan H.","family":"Noe","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"7","key":"des230001r1","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.","volume":"7","author":"Sbidian","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"des230001r2","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1001\/jamadermatol.2019.4029","article-title":"Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis.","volume":"156","author":"Armstrong","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"5","key":"des230001r3","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/j.jaad.2019.12.038","article-title":"Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: results from a network meta-analysis.","volume":"82","author":"Warren","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"des230001r4","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s13555-022-00690-5","article-title":"Cumulative clinical benefits of biologics in the treatment of patients with moderate-to-severe psoriasis over 1 year: a network meta-analysis.","volume":"12","author":"Blauvelt","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"des230001r5","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1080\/09546634.2020.1743811","article-title":"Targeted therapies for patients with moderate-to-severe psoriasis: a systematic review and network meta-analysis of PASI response at 1 year.","volume":"33","author":"Yasmeen","year":"2022","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"des230001r6","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13643-017-0473-z","article-title":"Approaches to interpreting and choosing the best treatments in network meta-analyses.","volume":"6","author":"Mbuagbaw","year":"2017","journal-title":"Syst Rev"},{"key":"des230001r7","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2022.151979","article-title":"Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis: a nationwide cohort study from the DANBIO and DERMBIO registries.","volume":"53","author":"Egeberg","year":"2022","journal-title":"Semin Arthritis Rheum"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2812066\/jamadermatology_blauvelt_2023_es_230001_1705092756.96988.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T17:53:31Z","timestamp":1705514011000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2812066"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,1]]},"references-count":7,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2023.4445","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1,1]]}}}